HumaGene, Inc.

HumaGene has developed IP processes for producing human fibrinogen and thrombin. With $1.2 MM in new funding, HumaGene will become profitable in 18 months.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Phoenix, AZ, US
  • Currency USD
  • Founded August 2006
  • Employees 2
  • Website humagene.com

Company Summary

HumaGene, Inc. (HG) has developed IP processes to produce the human form of fibrinogen and thrombin. We will sell active ingredients to (a) health care companies in the multi-billion dollar market and (b) academia/clinics.
Final R&D work as well as production have been scheduled for the next 18 months, after which time, HG will be profitable (has RWA customers).
CEO works with the Board, specialized consultants, and R&D/Production partners.

Team

  • Torben Riise
    CEO

    Torben Riise, a native of Denmark, has a background in science and business (PhD biotechnology; MBA in business economy) and has held executive positions in several large, international biotech companies for more than two decades. He has his own consulting business. He sits on the Boards of several upstart companies. Torben has served as Goodwill Ambassador for Denmark since 2001. Torben is not an investor in HumaGene.

    See Documents for details.

  • Jeffrey Zweiben
    Chariman, CFO

    Jeffrey Zweiben has an MBA and MA in mathematics from the University of Rochester. He has 30 years’ experience in business and IT as a co-owner and Vice President of Health Economics Group, a TPA (Third Party Administrator) managing employee benefit plans and related products.
    See Documents for details.

Advisors

  • Jeffrey Teibel
    Board Member
    Unconfirmed
    Per Fisher
    External Advisor
    Unconfirmed

Previous Investors

  • Jeffrey Teibel
    Board Member
    Unconfirmed
    Jens M. Beck
    External investor
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free